Sjögren's Syndrome
Autoimmune exocrinopathy destroying moisture-producing glands. MSC therapy suppresses lymphocytic infiltration and restores glandular function.
Sjögren's syndrome is a chronic autoimmune disease in which the immune system attacks exocrine glands — primarily the lacrimal (tear) and salivary glands — causing severe dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). Sjögren's affects approximately 3 million Americans and is the second most common autoimmune rheumatic disease after rheumatoid arthritis.
Beyond sicca symptoms, Sjögren's can involve systemic autoimmune manifestations: fatigue, arthritis, peripheral neuropathy, renal tubular acidosis, interstitial lung disease, and — in 5% of cases — lymphoma. Anti-SSA/Ro and anti-SSB/La antibodies are characteristic. Standard therapy is symptom management (artificial tears, saliva substitutes, hydroxychloroquine), with no therapy able to halt glandular destruction.
MSC therapy offers an immunological approach to Sjögren's — targeting the lymphocytic infiltration and autoantibody production that drives glandular destruction, rather than simply replacing what the immune system has destroyed.
MSCs suppress the Th17-driven lymphocytic infiltration of salivary and lacrimal glands that is central to Sjögren's pathology. Through PGE2, IDO, and TGF-β secretion, MSCs reduce the infiltrating CD4+ T-cell and B-cell populations, lower anti-SSA/SSB autoantibody titers, and promote Treg expansion that enforces local immune tolerance in glandular tissue.
Published clinical case series and small trials in primary Sjögren's syndrome have reported improvements in unstimulated salivary flow rate, subjective sicca symptoms, fatigue scores, and reductions in autoantibody titers following MSC infusion. One Chinese multicenter trial demonstrated maintained improvements in ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) at 48 weeks post-treatment.
True Regen coordinates salivary gland ultrasound, anti-SSA/SSB testing, Schirmer's test, and symptom scoring (ESSPRI) before and after treatment to objectively track glandular and immune response.
- Improved salivary flow rate and reduced oral dryness
- Decreased eye dryness and Schirmer test improvement
- Reduction in anti-SSA/SSB autoantibody titers
- Lower ESSDAI disease activity score
- Reduced fatigue and systemic autoimmune burden
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.